Dolutegravir: a new HIV integrase inhibitor for the treatment of HIV infection. (November 2014)

• Record Type: Journal Article
• Authors: Max, Blake; Vibhakar, Sonia
• Is Part Of: Future virology. Volume 9:Number 11(2014)
• Page Start: 967
• Page End: 978
• Publication Date: 2014-11
• Subjects: antiretroviral -- dolutegravir -- highly active antiretroviral therapy -- HIV-1 infection -- integrase strand transfer inhibitor -- Tivicay®; Virology -- Periodicals; Virus diseases -- Treatment -- Periodicals; 616.9101
• DOI: 10.2217/fvl.14.80
• Languages: English
• ISSNs: 1746-0794

Abstract

ABSTRACT : Dolutegravir is a second-generation HIV integrase strand transfer inhibitor (INSTI) and the most recent antiretroviral approved for treatment of HIV-1 infection. Dolutegravir in combination with two nucleoside reverse transcriptase inhibitors is one of the preferred regimens recommended by the Department of Health and Human Services HIV treatment guidelines for treatment-naive adults and adolescents. This recommendation is based on clinical trial data where dolutegravir demonstrated superiority compared with guideline preferred regimens containing efavirenz and ritonavir-boosted darunavir and noninferiority compared with first-generation INSTI, raltegravir. Dolutegravir also demonstrated superiority when compared with raltegravir in treatment-experienced, integrase-naive patients and clinical efficacy in patients with resistance to first-generation INSTIs. Overall, dolutegravir has demonstrated excellent tolerability, limited drug interactions, minimal drug resistance and once-daily dosing for treatment-naive patients.